Condition: MS



DESCRIPTION: Feeding high doses of LA to mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), has been found to slow disease progression. In these animals, LA feeding appeared to inhibit the migration of inflammatory T cells into the brain and spinal cord, possibly by inhibiting the activity of an enzyme known as matrix metalloproteinase (MMP)-9. A small pilot study designed to evaluate the safety of LA in 30 people with relapsing or progressive MS found that treatment with 1200-2400 mg/day of oral LA for 2 weeks was generally well-tolerated (see Safety), and that higher peak serum levels of LA were associated with greater decreases in serum MMP-9 levels. Larger, long-term clinical trials are needed to assess the safety and efficacy of LA in the treatment of MS.

Diseases MS is associated with:

Multiple sclerosis |

Symptoms associated with MS:

Leg pain | Nerve pain | Numbness | Pins and needles | Tingling |

List of EAP product(s) which may assist with MS :

ThioGel | ThioGel - L |




List of other EAP products:

OmniFlex | ThioGel | ThioGel - L |

 

Go back to RESOURCE HOME: Click here